CBIO

Crescent Biopharma Inc

• TipRanks·1d ago

  Crescent Biopharma: Buy Rating Reiterated as CR-001 Program Advances; 12-Month Price Target Maintained at $36

• Dow Jones·1d ago

  Crescent Biopharma Price Target Maintained With a $36.00/Share by HC Wainwright & Co.

• TipRanks·4d ago

  Crescent Biopharma (CBIO) Receives a New Rating from Wedbush

• TipRanks·4d ago

  Analysts Offer Insights on Healthcare Companies: McKesson (MCK), Crescent Biopharma (CBIO) and Glaukos (GKOS)

• TipRanks·4d ago

  Crescent Biopharma advances oncology pipeline and ADC programs

• Benzinga·4d ago

  Crescent Biopharma Says Global Phase 1/2 APOLLO Trial Of CR-002, a PD-L1-Targeted ADC, On Track To Commence Dosing This Quarter; Initial Data Expected In H2 2027; Phase 1/2 Trial Of CR-003 (SKB105), An ITGB6-Targeted ADC, Ongoing In China; Initial Data Expected In Q1 2027

• TipRanks·4d ago

  Crescent Biopharma completes dose escalation in ASCEND trial of CR-001

• NASDAQ·10/06 15:39

  HC Wainwright & Co. Upgrades Crescent Biopharma to Buy from Neutral

• TipRanks·10/06 10:58

  Crescent Biopharma (CBIO) Gets a Buy from Stifel Nicolaus

• Dow Jones·10/06 10:27

  Crescent Biopharma Raised to Buy From Neutral by HC Wainwright & Co.

• Dow Jones·10/06 10:27

  Crescent Biopharma Price Target Announced at $36.00/Share by HC Wainwright & Co.

• Benzinga·10/06 10:18

  HC Wainwright & Co. Upgrades Crescent Biopharma to Buy, Announces $36 Price Target

• TipRanks·10/06 10:15

  Crescent Biopharma upgraded to Buy from Neutral at H.C. Wainwright

• TipRanks·10/05 14:40

  Analysts’ Top Healthcare Picks: Novartis (NVS), Crescent Biopharma (CBIO)

• Dow Jones·10/05 12:15

  Crescent Biopharma Receives FDA Clearance for Investigational New Drug Application